Return to homepagePandemic Pact

To develop a live intranasal COVID-19 vaccine to generate both humoral (especially respiratory mucosal) and cellular acquired immune responses against SARS-CoV-2, based on a recombinant version of an attenuated nonhuman poxvirus called myxoma virus that has been engineered to co-express the four SARS-CoV-2 proteins (S, N, M and E) needed to produce secreted non-infectious virus-like particles that antigenically mimic the complete SARS CoV-2 virus.

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Emergent Ventures Fast Grants

  • Principal Investigator

    Dr. Grant McFadden

  • Research Location

    United States of America

  • Lead Research Institution

    Arizona State University

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract